Litcius/Paper detail

Dual β-lactam for treatment of pulmonary <i>Mycobacterium abscessus</i> in a child

Bradford Becken, Khalid M Dousa, John L. Johnson, Steven M. Holland, Robert A. Bonomo

2024Antimicrobial Agents and Chemotherapy11 citationsDOIOpen Access PDF

Abstract

ABSTRACT Treatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro . Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who developed pulmonary Mycobacterium abscessus infection and was treated with a multi-drug regimen including two β-lactam antibiotics, achieving both early clinical and microbiological cure. This case highlights the potential benefit of dual β-lactam therapy for the treatment of drug-resistant Mycobacterium abscessus infection.

Topics & Concepts

Mycobacterium abscessusAntibioticsMedicineBronchiectasisAntimicrobialMicrobiologyDrug resistanceLungNontuberculous mycobacteriaRegimenMycobacteriumBeta-lactamMycobacterium avium complexImmunologyBiologyInternal medicineTuberculosisPathologyMycobacterium research and diagnosisTuberculosis Research and EpidemiologyQuinazolinone synthesis and applications